The primary benefit of Alpelisib is its ability to target and inhibit the PI3K pathway, which is a major driver in certain types of cancer. This targeted approach can lead to more effective treatment outcomes with potentially fewer side effects compared to traditional chemotherapy. In clinical trials, Alpelisib has been shown to significantly improve progression-free survival in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer.
